{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6846e583cca944a48e6715d3/69b92f669246d31db41495c3?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The Relentless Mindset Behind Scaling a Drug Manufacturing Company | Philippe Clavel","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1773743870320-1af5b1bf-a35f-432a-99eb-4375cae1d46c.jpeg?height=200","description":"<p>Building a CDMO capable of taking therapies from early discovery to commercial supply requires more than scale. It requires scientific depth, operational discipline and a culture that embraces problems rather than avoids them.</p><p><br></p><p>This week on Making It In Manufacturing, Harry Sloan sat down with Philippe Clavel, CEO of Curapath, bringing decades of experience across pharmaceutical manufacturing, leadership and CDMO strategy.</p><p><br></p><p>In this episode, Philippe Clavel covers:</p><p><br></p><p>• The evolution of CuraPath from a university spin-off focused on polymer science to a drug delivery CDMO serving biotech and large pharmaceutical companies (00:00)</p><p><br></p><p>• Why deep scientific expertise in polymer science and lipid nanoparticles is essential for solving complex drug delivery challenges and improving manufacturing processes (02:29)</p><p><br></p><p>• How CuraPath transitioned from early-stage discovery work to commercial manufacturing, growing from 0% commercial revenue to roughly 30% within five years (05:14)</p><p><br></p><p>• The operational realities of scaling into GMP manufacturing, including building robust processes, documentation and training across the organisation (10:12)</p><p><br></p><p>• Why successful CDMO partnerships are built on trust, technical questioning and understanding the deeper motivations behind a customer’s drug development programme (17:00)</p><p><br></p><p>If you’re interested in the realities of scaling a specialist CDMO, building high-trust biotech partnerships and transforming scientific innovation into manufacturable therapies, this conversation offers valuable insight from someone leading that journey firsthand.</p><p><br></p><p>Follow ARTO</p><p><br></p><p>LinkedIn:   / artotalent  </p><p>Spotify: https://open.spotify.com/show/0kEcRZO...</p><p>Instagram: https://www.instagram.com/arto.talent...</p><p>TikTok: https://www.tiktok.com/@artotalent?_t...</p><p>Apple Podcasts: https://podcasts.apple.com/us/podcast...</p><p>Website: https://arto-talent.com/</p><p>Youtube: @life_sciences  </p><p><br></p><p>Philippe Clavel</p><p>LinkedIn:   / philippe-clavel-cdmo-gxapis  </p><p><br></p><p>Harry Sloan</p><p>  / harry-sloan-605620154  </p><p><br></p><p>Timestamps</p><p><br></p><p>00:00 Introduction</p><p>00:17 Overview of CuraPath and its drug delivery focus</p><p>02:29 What differentiates CuraPath as a CDMO</p><p>04:00 Balancing cost, scalability and complex modalities</p><p>05:14 Growth from discovery projects to commercial manufacturing</p><p>06:10 Expanding expertise from polymers to lipid nanoparticle technologies</p><p>07:41 Supporting customers across the full development journey</p><p>09:21 The significance of delivering a therapy reaching the market</p><p>10:12 Transitioning to GMP manufacturing and operational discipline</p><p>11:34 Challenges that come with scaling CDMO operations</p><p>13:27 Building a culture that embraces problems and deviations</p><p>15:27 Understanding customer motivations and building trust</p><p>18:24 Collaboration across supply chains within drug manufacturing</p><p>21:17 Maintaining company culture while scaling leadership</p><p>23:32 Encouraging challenge and empowerment within teams</p><p>27:13 Advice for business development professionals in CDMO</p><p>31:08 Future outlook for CuraPath and its pipeline</p><p>34:25 Personal motivation behind leading the company</p><p>39:02 Episode closing</p><p><br></p><p>#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #DrugDelivery #Biotech #LifeSciences</p>","author_name":"ARTO Talent"}